Technical Analysis for GLYC - GlycoMimetics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 1,2,3 Retracement Bearish | Bearish Swing Setup | 4.07% | |
| 180 Bearish Setup | Bearish Swing Setup | 4.07% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 4.07% | |
| Narrow Range Bar | Range Contraction | 4.07% | |
| Wide Bands | Range Expansion | 4.07% | |
| Oversold Stochastic | Weakness | 4.07% | |
| Calm After Storm | Range Contraction | 1.81% | |
| Narrow Range Bar | Range Contraction | 1.81% | |
| Outside Day | Range Expansion | 1.81% | |
| Wide Bands | Range Expansion | 1.81% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | 27 minutes ago |
| Up 3% | about 3 hours ago |
| Up 2% | about 3 hours ago |
| Bearish 180 Entry | about 4 hours ago |
| Non-ADX 1,2,3,4 Bearish Retracement Entry | about 4 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/09/2024
GlycoMimetics, Inc. Description
GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases. Its lead product includes GMI-1070, a glycomimetic drug candidate that acts as a pan-selectin antagonist has completed Phase II clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The company is also developing GMI-1271, a specific E-selectin antagonist, which it plans to initiate a Phase I dose-escalation clinical trials in healthy volunteers to be used in combination with chemotherapy to treat acute myeloid leukemia and potentially other hematologic cancers. In addition, its drug candidates comprise GMI-1051 and other drug candidates for pseudomonas virulence factors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Gaithersburg, Maryland.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Disease Drug Discovery Acute Myeloid Leukemia Chemotherapy Clinical Trial Product Testing Pseudomonas Sickle Cell Disease Hematologic Cancers Nursing Research
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.5299 |
| 52 Week Low | 0.256 |
| Average Volume | 1,801,119 |
| 200-Day Moving Average | 2.02 |
| 50-Day Moving Average | 2.10 |
| 20-Day Moving Average | 1.19 |
| 10-Day Moving Average | 0.58 |
| Average True Range | 0.20 |
| RSI (14) | 20.63 |
| ADX | 48.32 |
| +DI | 9.14 |
| -DI | 44.73 |
| Chandelier Exit (Long, 3 ATRs) | 1.80 |
| Chandelier Exit (Short, 3 ATRs) | 0.85 |
| Upper Bollinger Bands | 2.68 |
| Lower Bollinger Band | -0.30 |
| Percent B (%b) | 0.19 |
| BandWidth | 251.01 |
| MACD Line | -0.58 |
| MACD Signal Line | -0.50 |
| MACD Histogram | -0.0779 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.29 | ||||
| Resistance 3 (R3) | 0.30 | 0.29 | 0.29 | ||
| Resistance 2 (R2) | 0.29 | 0.28 | 0.29 | 0.29 | |
| Resistance 1 (R1) | 0.28 | 0.28 | 0.28 | 0.28 | 0.29 |
| Pivot Point | 0.28 | 0.28 | 0.27 | 0.27 | 0.28 |
| Support 1 (S1) | 0.26 | 0.27 | 0.26 | 0.26 | 0.25 |
| Support 2 (S2) | 0.26 | 0.27 | 0.26 | 0.25 | |
| Support 3 (S3) | 0.25 | 0.26 | 0.25 | ||
| Support 4 (S4) | 0.25 |
